FI112867B - 4-aminopyrrolo[2,3-d]pyrimidinderivat och deras användning - Google Patents

4-aminopyrrolo[2,3-d]pyrimidinderivat och deras användning Download PDF

Info

Publication number
FI112867B
FI112867B FI971225A FI971225A FI112867B FI 112867 B FI112867 B FI 112867B FI 971225 A FI971225 A FI 971225A FI 971225 A FI971225 A FI 971225A FI 112867 B FI112867 B FI 112867B
Authority
FI
Finland
Prior art keywords
phenyl
aminopyrrolo
pyrimidine
alkyl
alkoxy
Prior art date
Application number
FI971225A
Other languages
English (en)
Finnish (fi)
Other versions
FI971225A0 (sv
FI971225A (sv
Inventor
Martin Missbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI971225A0 publication Critical patent/FI971225A0/sv
Publication of FI971225A publication Critical patent/FI971225A/sv
Application granted granted Critical
Publication of FI112867B publication Critical patent/FI112867B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)
FI971225A 1994-09-29 1997-03-24 4-aminopyrrolo[2,3-d]pyrimidinderivat och deras användning FI112867B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH295394 1994-09-29
CH295394 1994-09-29
PCT/EP1995/003536 WO1996010028A1 (en) 1994-09-29 1995-09-08 PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE
EP9503536 1995-09-08

Publications (3)

Publication Number Publication Date
FI971225A0 FI971225A0 (sv) 1997-03-24
FI971225A FI971225A (sv) 1997-05-14
FI112867B true FI112867B (sv) 2004-01-30

Family

ID=4245363

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971225A FI112867B (sv) 1994-09-29 1997-03-24 4-aminopyrrolo[2,3-d]pyrimidinderivat och deras användning

Country Status (20)

Country Link
US (1) US5869485A (sv)
EP (1) EP0783505B1 (sv)
JP (1) JP4145955B2 (sv)
KR (1) KR970706288A (sv)
CN (1) CN1046731C (sv)
AT (1) ATE199553T1 (sv)
AU (1) AU694801B2 (sv)
BR (1) BR9509048A (sv)
CA (1) CA2200210A1 (sv)
DE (1) DE69520282T2 (sv)
DK (1) DK0783505T3 (sv)
ES (1) ES2157344T3 (sv)
FI (1) FI112867B (sv)
GR (1) GR3035996T3 (sv)
HU (1) HU222181B1 (sv)
MX (1) MX9702307A (sv)
NO (1) NO308108B1 (sv)
NZ (1) NZ293249A (sv)
PT (1) PT783505E (sv)
WO (1) WO1996010028A1 (sv)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
EP0912562A1 (en) * 1996-07-19 1999-05-06 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
ES2297864T3 (es) 1996-08-23 2008-05-01 Novartis Ag Pirrolopirimidinas sustituidas y procesos para su preparacion.
CA2266519C (en) 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
CN1134439C (zh) * 1997-03-19 2004-01-14 艾博特股份有限两合公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
AU7927498A (en) * 1997-08-05 1999-03-01 Pfizer Products Inc. 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
PL204628B1 (pl) * 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DK1212327T3 (da) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
SI1951724T1 (sl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
US7772231B2 (en) * 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
JP5156644B2 (ja) * 2006-01-25 2013-03-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 不飽和ｍＴＯＲ阻害剤
EA018144B1 (ru) * 2008-03-19 2013-05-30 Оси Фармасьютикалз, Инк. СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
DK2358720T3 (en) * 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
MX2012002997A (es) 2009-09-10 2012-08-01 Novartis Ag Derivados de eter de los heteroarilos biciclicos.
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
EP2582680A1 (en) 2010-06-17 2013-04-24 Novartis AG Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CN104853806A (zh) 2012-05-14 2015-08-19 理查德·G·佩斯泰尔 使用ccr5调节剂治疗癌症
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
US10550124B2 (en) * 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019119486A1 (zh) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung

Also Published As

Publication number Publication date
EP0783505B1 (en) 2001-03-07
PT783505E (pt) 2001-08-30
AU694801B2 (en) 1998-07-30
CN1164234A (zh) 1997-11-05
MX9702307A (es) 1998-04-30
BR9509048A (pt) 1998-01-06
EP0783505A1 (en) 1997-07-16
DK0783505T3 (da) 2001-07-02
US5869485A (en) 1999-02-09
CN1046731C (zh) 1999-11-24
CA2200210A1 (en) 1996-04-04
GR3035996T3 (en) 2001-09-28
NO971342D0 (no) 1997-03-21
HUT76785A (en) 1997-11-28
AU3564395A (en) 1996-04-19
DE69520282D1 (de) 2001-04-12
NO971342L (no) 1997-03-21
JP4145955B2 (ja) 2008-09-03
JPH10506624A (ja) 1998-06-30
NZ293249A (en) 1999-04-29
KR970706288A (ko) 1997-11-03
NO308108B1 (no) 2000-07-24
FI971225A0 (sv) 1997-03-24
ATE199553T1 (de) 2001-03-15
WO1996010028A1 (en) 1996-04-04
HU222181B1 (hu) 2003-04-28
FI971225A (sv) 1997-05-14
ES2157344T3 (es) 2001-08-16
DE69520282T2 (de) 2001-08-09

Similar Documents

Publication Publication Date Title
FI112867B (sv) 4-aminopyrrolo[2,3-d]pyrimidinderivat och deras användning
KR102366670B1 (ko) O-아미노헤테로아릴알키닐기를 함유한 화합물 및 이의 제조 방법과 용도
JP3270830B2 (ja) 化合物
KR900004693B1 (ko) 4,5,6-치환-n-(치환페닐)-2-피리미딘아민, 그 제조방법 및 그 화합물이 들어있는 조성물
EP2650293A1 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
KR101716068B1 (ko) 신규한 퀴놀린 유도체 및 이의 적용
TW201638092A (zh) 嘧啶並吡咯類化合物、其製備方法、藥用組合物及其應用
WO2002032872A1 (en) Nitrogenous aromatic ring compounds
CZ302359B6 (cs) Triazolové slouceniny a jejich použití
KR20190045399A (ko) 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
SK6222003A3 (en) Naphthalene derivatives, process for their preparation and their use in pharmaceutical compositions
FI100530B (sv) Förfarande för framställning av substituerade diaminoftalimider och de ras analoger
TW200526632A (en) New compounds
JPH09501171A (ja) ５ｈｔ１ｄ受容体アンタゴニストとしてのアミド誘導体
WO1993022290A1 (en) Novel substituted tertiary amino compound or salt thereof
JPWO2005012258A1 (ja) タンパク質キナーゼ阻害剤
CZ97897A3 (en) Novel derivatives of 2,3-benzodiazepine
CN110835334B (zh) 吲哚取代唑类化合物及其用途
JPH0699309B2 (ja) 離脱症候群関連障害治療用医薬製品
KR20150134731A (ko) 오로라 키나아제 억제 활성을 갖는 신규한 트리아졸일살리실아마이드 유도체
CN107743489A (zh) 用于治疗免疫疾病、炎性疾病或者癌症的7‑(吗啉‑4‑基)吡唑并[1,5‑a]嘧啶衍生物
CZ23799A3 (cs) Farmaceutický přípravek obsahující 5HT2C antagonistu a D2 antagonistu
JPH0377191B2 (sv)
Barlin et al. Imidazo [1, 2-b] pyridazines. XIII. Syntheses and Central Nervous System Activities of Some 2-Benzyl (phenethyl, biphenyl-4'-yl, 6'-methylnaphthalen-2'-yl, t-butyl and cyclohexyl)-3-methoxy (acylaminomethyl and dimethylaminomethyl)-6-(variously substituted) imidazo [1, 2-b] pyridazines
EP1556359B1 (en) Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases